PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Update

PDS Biotechnology Corporation (NASDAQ:PDSB) saw a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 2,035,289 shares, a decrease of 24.3% from the February 26th total of 2,688,806 shares. Based on an average trading volume of 221,785 shares, the days-to-cover ratio is presently 9.2 days. Currently, 4.3% of the company’s shares are short sold.

PDS Biotechnology Trading Up 12.8%

Shares of PDS Biotechnology stock traded up $0.07 during trading hours on Tuesday, reaching $0.61. The stock had a trading volume of 839,009 shares, compared to its average volume of 606,914. The firm has a market capitalization of $31.68 million, a price-to-earnings ratio of -0.74 and a beta of 1.20. PDS Biotechnology has a 1 year low of $0.51 and a 1 year high of $1.92. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. The firm has a 50 day simple moving average of $0.71 and a two-hundred day simple moving average of $0.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in PDS Biotechnology during the fourth quarter worth approximately $25,000. Armistice Capital LLC purchased a new position in shares of PDS Biotechnology in the 4th quarter valued at $2,182,000. Commonwealth Equity Services LLC lifted its holdings in shares of PDS Biotechnology by 117.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after acquiring an additional 106,300 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of PDS Biotechnology by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after acquiring an additional 38,399 shares in the last quarter. Finally, Tempus Wealth Planning LLC boosted its position in PDS Biotechnology by 29.3% during the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock worth $48,000 after purchasing an additional 14,000 shares during the period. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.